Profitability
Weight: 15%
F
0
- 5yr Avg ROIC -8.9%
- Operating Margin Trend -171.80 pp/yr
KYMR
Kymera Therapeutics, Inc.
AlphaQuality composite grade, weighted for high-growth software businesses.
⚠ 5 of the last 5 fiscal years showed negative net income — AlphaQuality will not grade above F for persistent unprofitability in a high-growth software business.
Grade overrides the 10.8 pillar composite — hard gates always win.
Capital Efficiency
Weight: 15%
F
0
- 5yr Avg ROE -11.9%
- 5yr Share-Count CAGR 15.2%
Growth Quality
Weight: 35%
F
15
- 5yr Revenue CAGR -14.3%
- 5yr EPS CAGR 0.0%
- Revenue-Growth Years (5) 2/5
Cash Generation
Weight: 20%
F
0
- 5yr FCF Margin -345.0%
- 5yr FCF/NI Conversion 0.00x
Balance Sheet
Weight: 10%
F
25
- Net Debt / EBITDA 10.00x
- Interest Coverage (EBIT/Int) -1250.50x
- Altman Z-Score 28.99
Stability
Weight: 5%
C+
62
- EPS Volatility (σ/μ) 0.00
- Piotroski F-Score 2
- Negative-Revenue Years (5) 3/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.Not enough curated-guru data to call a flow.
- Wood sold -100%